Editas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10 – GlobeNewswire (press release)
Press Telegraph |
Editas Medicine Receives EMA's Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10
GlobeNewswire (press release) 26, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the European Medicines Agency (EMA) granted Orphan Medicinal Product designation to EDIT-101, a pre-clinical, CRISPR-based … Editas Medicine, Inc. (NASDAQ:EDIT) Moving Today – Down $0.85 |
